Trial Profile

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 22 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Dec 2025 According to a Crinetics Pharmaceuticals media release, first patient has been dosed in the CALM-CAH phase 3 trial for the proposed treatment of classic congenital adrenal hyperplasia (CAH).
06 Nov 2025 According to a Crinetics Pharmaceuticals media release, company expects the first patients to randomize in this trial in the fourth quarter of 2025.
07 Aug 2025 According to a Crinetics Pharmaceuticals media release, company expects to initiate the CALM-CAH Phase 3 study in adults with CAH in the second half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com